Researchers identify distinct molecular profiles in Down syndrome

A new study published in Nature Communications by researchers from the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz Medical Campus reports a significant breakthrough.

Avidity to raise $400M; Sato pays Arcutis $25M upfront to license topical roflumilast in Japan

Plus, news about Xencor, Otsuka, Typewriter Therapeutics, Cassava Sciences, Enveric Biosciences, Viking Therapeutics and Janux Therapeutics: Next up in the PIPE bonanza: RNA company Avidity

March 1, 2024

Sandoz unveils global action plan to improve access to biosimilars

As the spotlight trains on access to biosimilars, Novartis’ generics unit on Thursday released a global action plan to boost biosimilar adoption by 2030. The

June 15, 2023

Avenge Bio, a cell therapy biotech from Rice, is closed

Cell therapy startup Avenge Bio has shut down, Endpoints News has learned. The company ceased all operations and sold its lead asset, Xontogeny CEO Chris

August 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.